Literature DB >> 25801244

Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.

Biao Wang1, Shuo Li, Xin Meng, Hong Shang, Yifu Guan.   

Abstract

The expression of ATP-dependent efflux pump P-glycoprotein (P-gp) in cancer cells generally results in multidrug resistance (MDR) to chemotherapeutic drugs, which is the main cause of chemotherapy failure in cancer treatment. The intracellular drug levels could be increased by some MDR reversal agents that inhibited the drug efflux activity of P-gp. The synthesized DNA nucleic acids of G-quadruplex represent a novel and unique class of anti-cancer agents. While there was no report on the roles of DNA G-quadruplex oligonucleotides (GQ-ODNs) in the MDR reversal, the present study was performed to investigate the ability of synthesized GQ-ODNs to reverse P-gp-mediated MDR and its mechanism in paclitaxel (PTX)-resistant SKOV3 (SKOV3/PTX) cells and their sensitive cell lines SKOV3. The ability of GQ-ODNs to reverse drug resistance was evaluated by MTS assay. The results showed that GQ-ODNs can reverse PTX resistance effectively. The potential of GQ-ODNs as reversal agents was evaluated with the nude mice tumor xenograft model and showed that the co-administration of the GQ-ODNs and PTX had better effects and was also more evident than treatment with only PTX. The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. The presence of GQ-ODNs efficiently decreased the P-gp expression, showing that GQ-ODNs could reverse P-gp-mediated MDR by decreasing the expression of P-gp. This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Thus, the synthesized GQ-ODNs may be a potential inhibitor to overcome drug resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801244     DOI: 10.1007/s13277-015-3333-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

Review 1.  RNA G-quadruplexes: G-quadruplexes with "U" turns.

Authors:  Tani Agarwal; Gopal Jayaraj; Satya Prakash Pandey; Prachi Agarwala; Souvik Maiti
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines.

Authors:  Bruna Scaggiante; Barbara Dapas; Gabriele Grassi; Giorgio Manzini
Journal:  FEBS J       Date:  2006-04       Impact factor: 5.542

3.  Geometric formalism for DNA quadruplex folding.

Authors:  Mateus Webba da Silva
Journal:  Chemistry       Date:  2007       Impact factor: 5.236

4.  Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer.

Authors:  Naijie Jing; Qiqing Zhu; Ping Yuan; Yidong Li; Li Mao; David J Tweardy
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

5.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 6.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.

Authors:  R Z Yusuf; Z Duan; D E Lamendola; R T Penson; M V Seiden
Journal:  Curr Cancer Drug Targets       Date:  2003-02       Impact factor: 3.428

7.  T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling.

Authors:  Priya Weerasinghe; Yifei Li; Yongli Guan; Ruiwen Zhang; David J Tweardy; Naijie Jing
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

8.  Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.

Authors:  D H Johnson; D M Paul; K R Hande; Y Shyr; C Blanke; B Murphy; M Lewis; R F De Vore
Journal:  J Clin Oncol       Date:  1996-07       Impact factor: 44.544

9.  Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Authors:  Fiona Simpkins; Jerome L Belinson; Peter G Rose
Journal:  Gynecol Oncol       Date:  2007-07-23       Impact factor: 5.482

10.  Screening and improvement of an anti-VEGF DNA aptamer.

Authors:  Yoshihiko Nonaka; Koji Sode; Kazunori Ikebukuro
Journal:  Molecules       Date:  2010-01-07       Impact factor: 4.411

View more
  8 in total

1.  Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells.

Authors:  Ai-Wen Zheng; Ya-Qing Chen; Ling-Qin Zhao; Jian-Guo Feng
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

2.  Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.

Authors:  Xiao-Han Tang; Suo Deng; Meng Li; Mei-Song Lu
Journal:  Tumour Biol       Date:  2015-11-16

Review 3.  Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.

Authors:  Sweta Mishra; Johnathan R Whetstine
Journal:  Mol Cell Biol       Date:  2016-01-11       Impact factor: 4.272

4.  Search for ABCB1 Modulators Among 2-Amine-5-Arylideneimidazolones as a New Perspective to Overcome Cancer Multidrug Resistance.

Authors:  Aneta Kaczor; Márta Nové; Annamária Kincses; Gabriella Spengler; Ewa Szymańska; Gniewomir Latacz; Jadwiga Handzlik
Journal:  Molecules       Date:  2020-05-11       Impact factor: 4.411

5.  The ABCB1 3435C > T polymorphism influences docetaxel transportation in ovarian cancer.

Authors:  Beibei Yin; Ping Lu; Jing Liang; Wei Zhang; Meng Xin; Ke Pei; Yan Li
Journal:  J Int Med Res       Date:  2019-09-06       Impact factor: 1.671

Review 6.  Research Progress and Prospects of Autophagy in the Mechanism of Multidrug Resistance in Tumors.

Authors:  Wenqing Long; Lijun Zhang; Yuxing Wang; Haijuan Xie; Lin Wang; Hongnu Yu
Journal:  J Oncol       Date:  2022-01-30       Impact factor: 4.375

Review 7.  Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.

Authors:  Robert Cornelison; Danielle C Llaneza; Charles N Landen
Journal:  Int J Mol Sci       Date:  2017-10-18       Impact factor: 5.923

8.  The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer.

Authors:  Yanqing Wang; Xiaoyin Qiao; Xiao Yang; Mengqin Yuan; Shu Xian; Li Zhang; Dongyong Yang; Shiyi Liu; Fangfang Dai; Zhikai Tan; Yanxiang Cheng
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.